A therapy that fits her life
Your patients can feel confident in the
convenience of Divigel®
Highly concentrated estradiol gel: 0.1%—a small amount
of gel applied once daily to a small area (5"x7") of skin on
the upper thigh1
Small packets are portable, discreet, and easy to use at home or away
Once-daily application, even at bedtime, for all-day, all-night estradiol coverage1
Your patients can feel confident in t/> convenience of Divigel®
Highly concentrated estradiol gel: 0.1%—a small amou/> of gel applied once daily to a small area (5"x7") of skin /> the upper thigh1
Small packets are portable, discreet, and easy to use at home or away
Once-daily application, even at bedtime, for all-day, all-night estradiol coverage1

Patients can feel confident in effective relief
from a lower dose

Current American Congress of Obstetricians and Gynecologists (ACOG) and North American Menopause Society (NAMS) guidelines recommend using the lowest effective dose of estrogen, for the shortest duration of time, for treatment of vasomotor symptoms.3,16,17

Divigel® offers 3 low-dose options, including the lowest FDA-approved dose (0.25 mg/day) of plant-based estradiol for effective relief of moderate to severe hot flashes.1,5-7

Patients can be confident that Divigel® contains bioidentical estradiol3 derived from plant sources

There are no “natural” or compounded estradiol products that are
FDA-approved3
However, Divigel® contains 17β-estradiol that is bioidentical to the estrogen produced naturally in a woman’s body prior to menopause1,3
The estradiol in Divigel® is synthesized from plant sources, such as yams, soy, or sunflowers4
Patients can be confident Divigel® is affordable
Divigel® has broad coverage on most insurance plans
Eligible patients can enroll in the Patient Savings Program to save on
12 months of Divigel®

Patients can feel confident in effective relief from a lower dose

Current American Congress of Obstetricians and Gynecologists (ACOG) and North American Menopause Society (NAMS) guidelines recommend using the lowest effective dose of estrogen, for the shortest duration of time, for treatment of vasomotor symptoms.3,16,17

Divigel® offers 3 low-dose options, including the lowest FDA-approved dose (0.25 mg/day) of plant-based estradiol for effective relief of moderate to severe hot flashes.1,5-7

Patients can be confident that Divigel® contains bioidentical estradiol3 derived from plant sources

There are no “natural” or compounded estradiol products that are
FDA-approved3
However, Divigel® contains 17?-estradiol that is bioidentical to the estrogen produced naturally in a woman’s body prior to menopause1,3
The estradiol in Divigel® is synthesized from plant sources, such as yams, soy, or sunflowers4
Patients can be confident Divigel® is affordable
Divigel® has broad coverage on most insurance plans
Eligible patients can enroll in the Patient Savings Program to save on 4 months of Divigel®
Divigel® (estradiol gel) 0.1% is indicated for the treatment of moderate to severe vasomotor symptoms due to menopause.

Important Safety Information for Healthcare Providers

WARNING: ENDOMETRIAL CANCER, CARDIOVASCULAR DISORDERS, BREAST CANCER and PROBABLE DEMENTIA

See Full Prescribing Information for complete Boxed Warning

Estrogen-Alone Therapy
  • There is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens
  • Estrogen-alone therapy should not be used for the prevention of cardiovascular disease or dementia
  • The Women’s Health Initiative (WHI) estrogen-alone substudy reported increased risks of stroke and deep vein thrombosis (DVT)
  • The WHI Memory Study (WHIMS) estrogen-alone ancillary study of the WHI reported an increased risk of probable dementia in postmenopausal women 65 years of age or older
Estrogen Plus Progestin Therapy
  • Estrogen plus progestin therapy should not be used for the prevention of cardiovascular disease or dementia
  • The WHI estrogen plus progestin substudy reported increased risks of stroke, DVT, pulmonary embolism (PE), and myocardial infarction (MI)
  • The WHI estrogen plus progestin study reported increased risks of invasive breast cancer
  • The WHIMS estrogen plus progestin ancillary study of WHI reported an increased risk of probable dementia in postmenopausal women 65 years of age and older

Divigel® should not be used in women with undiagnosed abnormal genital bleeding; known, suspected, or history of breast cancer; known or suspected estrogen-dependent neoplasia; active DVT, PE, or history of these conditions; active arterial thromboembolic disease or a history of these conditions; known anaphylactic reaction or angioedema to Divigel®; known liver impairment or disease; known protein C, protein S, or antithrombin deficiency, or other known thrombophilic disorders; or known or suspected pregnancy.

Estrogens increase the risk of gallbladder disease.

Discontinue estrogen if severe hypercalcemia, loss of vision, severe hypertriglyceridemia or cholestatic jaundice occurs.

Monitor thyroid function in women on thyroid replacement therapy.

The most common adverse reactions (incidence ≥ 5 percent) are breast tenderness, metrorrhagia, vaginal mycosis, nasopharyngitis, and upper respiratory tract infection.

Patients should be started with the lowest effective dose and the dose should be evaluated periodically.

Alcohol-based gels are flammable. Patients should avoid fire, flame or smoking until the gel has dried.

Please see Full Prescribing Information, including Boxed Warning and Patient Counseling Information. For more information, call 732-721-0070 or visit www.divigel.com.

You are encouraged to report negative side effects to Vertical Pharmaceuticals, LLC at 1-877-95-VERTI (1-877-958-3784), or to the FDA by visiting www.fda.gov/medwatch or calling 1-800-FDA-1088.

Important Safety Information & Indication
Divigel® (estradiol gel) 0.1% is indicated for the treatment of moderate to severe vasomotor symptoms due to menopause.

Important Safety Information for Healthcare Providers

WARNING: ENDOMETRIAL CANCER, CARDIOVASCULAR DISORDERS, BREAST CANCER and PROBABLE DEMENTIA

See Full Prescribing Information for complete Boxed Warning

Estrogen-Alone Therapy
  • There is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens
  • Estrogen-alone therapy should not be used for the prevention of cardiovascular disease or dementia
  • The Women’s Health Initiative (WHI) estrogen-alone substudy reported increased risks of stroke and deep vein thrombosis (DVT)
  • The WHI Memory Study (WHIMS) estrogen-alone ancillary study of the WHI reported an increased risk of probable dementia in postmenopausal women 65 years of age or older
Estrogen Plus Progestin Therapy
  • Estrogen plus progestin therapy should not be used for the prevention of cardiovascular disease or dementia
  • The WHI estrogen plus progestin substudy reported increased risks of stroke, DVT, pulmonary embolism (PE), and myocardial infarction (MI)
  • The WHI estrogen plus progestin study reported increased risks of invasive breast cancer
  • The WHIMS estrogen plus progestin ancillary study of WHI reported an increased risk of probable dementia in postmenopausal women 65 years of age and older

Divigel® should not be used in women with undiagnosed abnormal genital bleeding; known, suspected, or history of breast cancer; known or suspected estrogen-dependent neoplasia; active DVT, PE, or history of these conditions; active arterial thromboembolic disease or a history of these conditions; known anaphylactic reaction or angioedema to Divigel®; known liver impairment or disease; known protein C, protein S, or antithrombin deficiency, or other known thrombophilic disorders; or known or suspected pregnancy.

Estrogens increase the risk of gallbladder disease.

Discontinue estrogen if severe hypercalcemia, loss of vision, severe hypertriglyceridemia or cholestatic jaundice occurs.

Monitor thyroid function in women on thyroid replacement therapy.

The most common adverse reactions (incidence ≥ 5 percent) are breast tenderness, metrorrhagia, vaginal mycosis, nasopharyngitis, and upper respiratory tract infection.

Patients should be started with the lowest effective dose and the dose should be evaluated periodically.

Alcohol-based gels are flammable. Patients should avoid fire, flame or smoking until the gel has dried.

Please see Full Prescribing Information, including Boxed Warning and Patient Counseling Information. For more information, call 732-721-0070 or visit www.divigel.com.

You are encouraged to report negative side effects to Vertical Pharmaceuticals, LLC at 1-877-95-VERTI (1-877-958-3784), or to the FDA by visiting www.fda.gov/medwatch or calling 1-800-FDA-1088.